Optimizing Treatment and Patient Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

Optimizing Treatment and Patient Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

Optimizing Treatment and Patient Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer
RestartResume

Tune in as 2 experts navigate management strategies for emerging data in BRAF mCRC with insights on biomarker testing, patient selection, and more!

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?

    Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Julien Taieb, MD, PhD
    Professor, Sorbonne Paris Cité, Paris Descartes University
    GI Oncology Department, Georges Pompidou European Hospital, APHP
    Paris, France 

    Honoraria for Advisory or Speaker Role: Merck

    Faculty:
    Scott Kopetz, MD, PhD
    Professor
    The University of Texas MD Anderson Cancer Center
    Houston, TX 

    No relevant financial relationships 

    Reviewers/Content Planners/Authors:

    • Libby Lurwick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply molecular profiling strategies that improve therapeutic and patient selection in BRAF V600E-mutated metastatic colorectal cancer (mCRC)
    • Formulate treatment algorithms that enhance the management of patients with BRAF V600E-mutated mCRC
  • Target Audience

    This activity is designed to meet the educational needs of oncologists and pathologists in Europe and Asia Pacific region.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free